Comment on ‘Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study’

Publisher： Karger

E-ISSN： 1423-0232|80|1-2|138-139

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.1-2, 2011-06, pp. : 138-139

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Regarding ‘Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study’

By  

Oncology, Vol. 80, Iss. 1-2, 2011-06 ,pp. : 135-137

Karger

Access to resources Recommend Favorite

Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study

By  

Oncology, Vol. 78, Iss. 5-6, 2010-08 ,pp. : 376-381

Karger

Access to resources Recommend Favorite

Bevacizumab + Capecitabine as Maintenance Therapy after Initial Bevacizumab + XELOX Treatment in Previously Untreated Patients with Metastatic Colorectal Cancer: Phase III ‘Stop and Go' Study Results - A Turkish Oncology Group Trial

By  

Oncology, Vol. 85, Iss. 6, 2013-11 ,pp. : 328-335

Karger

Access to resources Recommend Favorite

Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer

By  

Oncology, Vol. 77, Iss. 2, 2009-07 ,pp. : 113-119

Karger

Access to resources Recommend Favorite

5-Fluorouracil, Leucovorin and Oxaliplatin plus Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer: A Single-Institute Study

By  

Oncology, Vol. 72, Iss. 1-2, 2007-10 ,pp. : 4-9

Karger

Access to resources Recommend Favorite